Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending AcquisitionGlobeNewsWire · 2 days ago
Realbotix Announces Additional Draw under Bridge Loan from OnconetixBusiness Wire · 2 days ago
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Onconetix (NASDAQ:ONCO) Critical ComparisonDefense World · Oct 10, 2026
SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)GlobeNewsWire · Sep 24, 2026
CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending AcquisitionGlobeNewsWire · Sep 14, 2026
Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending AcquisitionGlobeNewsWire · Sep 14, 2026Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$4,505.00 | -$1.28 | Beat |
| May 13, 2026 | – | -$6.71 | |
| Mar 12, 2026 | – | $12.58 | |
| Nov 13, 2025 | – | -$31.25 | |
| Aug 14, 2025 | -$204.00 | -$2.03 | Beat |
| Jun 12, 2025 | -$348.50 | $10.59 | Beat |